---
title: "MapLight Therapeutics (MPLT) news: IPO and offering"
url: "https://aibio.space/companies/maplight-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "MPLT IPO and offering news: MapLight annual report details $200 million Series D preferred financing. MapLight Therapeutics, Inc."
---

MPLT MapLight Therapeutics, Inc. NASDAQ · United States

# MapLight Therapeutics (MPLT) news MPLT IPO and offering news

Financings · 2026-09-23

## [MapLight resale registration for 13.2 million private-placement shares takes effect](https://aibio.space/news/maplight-resale-registration-13-2-million-private-placement-shares/)

MapLight's resale prospectus lets the investors in its $150.0 million August placement sell up to 13,181,055 shares. The company receives no proceeds from those sales.

## Latest MapLight Therapeutics news

1. 2026-08-13 Financings [MapLight agrees $150 million private placement of shares and pre-funded warrants](https://aibio.space/news/maplight-agrees-150-million-private-placement-shares-pre-funded/) MapLight agreed to sell 9,197,887 voting shares at $11.38 and pre-funded warrants for 3,983,168 more shares, for about $150.0 million gross before fees.
2. 2026-08-13 Financings [MapLight reports $351.3 million in cash and investments, sees funding through 2028](https://aibio.space/news/maplight-reports-351-3-million-cash-investments-sees-funding-through/) MapLight reported $351.3 million in cash and investments at June 30, 2026 and cited funding through 2028. It also agreed to a private placement of about $150.0 million at $11.38 a share. Six-month operating cash use was $96.0 million.
3. 2026-07-30 Financings [Novo Holdings cuts MapLight stake below 5% after July 30 share sales](https://aibio.space/news/novo-holdings-cuts-maplight-stake-below-5-percent-after-july-30-share/) The Danish investor sold 1.6 million shares in open-market trades at $12.00 to $15.00 and reported 2,086,622 shares left, about 4.9%.
4. 2026-03-26 Financings [MapLight annual report details $200 million Series D preferred financing](https://aibio.space/news/maplight-annual-report-details-200-million-series-d-preferred/) The 2025 financing closed in two parts before the IPO. Holders tied to board members were among the buyers, the proxy shows.
5. 2025-10-28 Financings [MapLight IPO closes; additional-share option brings gross proceeds to $288.4 million](https://aibio.space/news/maplight-ipo-closes-additional-share-option-brings-gross-proceeds-288/) MapLight Therapeutics closed its initial public offering at $17.00 a share, and the underwriters exercised their option for more shares in full. Its lead drug has no Phase 2 results yet.

## MapLight Therapeutics at a glance

- **Ticker**: MPLT

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $304.7 million

### Related companies

- [Evolus](https://aibio.space/companies/evolus/) NASDAQ: EOLS
- [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) NASDAQ: LSTA
- [Nektar Therapeutics](https://aibio.space/companies/nektar-therapeutics/) NASDAQ: NKTR
- [Assembly Biosciences](https://aibio.space/companies/assembly-biosciences/) NASDAQ: ASMB
- [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) NASDAQ: AMRX
- [TherapeuticsMD](https://aibio.space/companies/therapeuticsmd/) NASDAQ: TXMD
- [Soligenix](https://aibio.space/companies/soligenix/) NASDAQ: SNGX
- [Lipella Pharmaceuticals](https://aibio.space/companies/lipella-pharmaceuticals/) OTC: LIPO

### Also on NASDAQ

- [AC Immune SA](https://aibio.space/companies/ac-immune/) ACIU
- [Cronos Group](https://aibio.space/companies/cronos/) CRON
- [Niki BioSolutions](https://aibio.space/companies/niki-biosolutions/) NIKI
- [OnKure Therapeutics](https://aibio.space/companies/onkure-therapeutics/) OKUR
- [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) ABUS
- [BioCryst Pharmaceuticals](https://aibio.space/companies/biocryst-pharmaceuticals/) BCRX

## MapLight Therapeutics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$138.3 million](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/) | [$68.5 million](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/) |
| Net income (loss) | [-$161.2 million](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/) | [-$77.6 million](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/) |
| Cash from operations | [-$138.1 million](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/) | [-$78.8 million](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/) |
| Cash and equivalents | [$46.7 million](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/) | [$38.3 million](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/) |
| Short-term investments | [$258.4 million](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/) | [$70.5 million](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $71.6 million, plus short-term investments of $233.1 million, $304.7 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Analysis

- Opinion Outperform Medium conviction 2026-10-28 [MapLight Therapeutics: Outperform. Near cash, but the drug must repeat its win](https://aibio.space/analysis/maplight-therapeutics-phase-3-cost/) At $7.97 a share, MapLight trades at roughly the cash we estimate it holds, so investors pay little for a schizophrenia drug with one moderate Phase 2 win that still needs a second trial. We rate the shares Outperform.

Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/).

## Questions about MapLight Therapeutics

When did MapLight Therapeutics go public?

Our latest story on this, dated Mar 26, 2026: "MapLight annual report details $200 million Series D preferred financing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/maplight-annual-report-details-200-million-series-d-preferred/).

Has MapLight Therapeutics raised money recently?

Our latest story on this, dated Aug 13, 2026: "MapLight agrees $150 million private placement of shares and pre-funded warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/maplight-agrees-150-million-private-placement-shares-pre-funded/).

What is the ticker symbol of MapLight Therapeutics?

MapLight Therapeutics, Inc. trades under the ticker MPLT on NASDAQ.

Where is MapLight Therapeutics listed?

MapLight Therapeutics, Inc. is listed on NASDAQ.

What is the SEC CIK of MapLight Therapeutics?

The SEC Central Index Key (CIK) for MapLight Therapeutics, Inc. is 1770069. Its filings are on SEC EDGAR.

How many shares does MapLight Therapeutics have outstanding?

42,436,326 shares as of 2026-03-19, per the cover page of its 10-K filed 2026-03-26.

Which country or territory is MapLight Therapeutics listed under?

Our directory records MapLight Therapeutics, Inc. under United States.

What does MapLight Therapeutics do?

Our directory classifies MapLight Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of MapLight Therapeutics?

The ISIN recorded for MapLight Therapeutics, Inc. is US56565P1030.

Does aibio.space cover MapLight Therapeutics?

aibio.space lists MapLight Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is MapLight Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

Is MapLight Therapeutics profitable?

MapLight Therapeutics, Inc. reported a net loss of $161.2 million for the fiscal year ended Dec 31, 2025, and used $138.1 million of cash in operations, per its annual report to the SEC.

How much does MapLight Therapeutics spend on research and development?

$138.3 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does MapLight Therapeutics have?

$304.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

What is the latest MapLight Therapeutics (MPLT) stock news?

Our latest story on MapLight Therapeutics, dated Sep 23, 2026: "MapLight resale registration for 13.2 million private-placement shares takes effect". MapLight's resale prospectus lets the investors in its $150.0 million August placement sell up to 13,181,055 shares. The company receives no proceeds from those sales. [Source](https://aibio.space/news/maplight-resale-registration-13-2-million-private-placement-shares/).

## Investor discussion: MapLight Therapeutics

Members talk about MapLight Therapeutics (MPLT). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at MapLight Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-09-23 Financing The SEC declared the selling-stockholder registration effective. [Source](https://www.sec.gov/Archives/edgar/data/1770069/999999999526003044/xslEFFECTX01/primary_doc.xml)
2. 2026-08-14 Financing The later resale prospectus confirms the private placement closed. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526399452/d546679d424b3.htm)
3. 2026-08-13 Financing MapLight agreed a private placement with common shares and pre-funded warrants. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/d48818d8k.htm)
4. 2026-08-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/d48818dex991.htm)
5. 2026-06-18 Leadership The company reported its CFO separation and appointed an interim CFO; it said the separation was unrelated to financial-reporting concerns. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526276065/d227825d8k.htm)
6. 2025-10-29 Financing The underwriters full additional-share option settled. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312525255041/d89036d8k.htm)
7. 2025-10-28 Financing The IPO initial closing and a concurrent private placement closed; the private share count is unreconciled. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312525255041/d89036d8k.htm)
8. 2025-10-26 Financing MapLight signed underwriting and concurrent private-placement purchase agreements. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312525255041/d89036d8k.htm)
9. 2025-09-19 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312525209084/d741179ds1.htm)
10. 2025-07-18 Financing MapLight entered a Series D purchase agreement; the annual report records $200 million gross issued during the year. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/mplt-20251231.htm)

## Investor questions about MapLight Therapeutics

### Where is MapLight listed?

The latest quarterly cover identifies the Nasdaq Global Select Market and the MPLT symbol. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/mplt-20260630.htm)

### How much cash and investments did it report?

The company reported approximately $351.3 million at 2026-06-30, including investments. This is not a cash-only figure. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/mplt-20260630.htm)

### What funding horizon did management give?

The quarterly report projected funding through 2028, including expected placement proceeds and subject to operating assumptions. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/mplt-20260630.htm)

### Did the later placement close?

The later resale prospectus says the private placement closed on 2026-08-14. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526399452/d546679d424b3.htm)

### Were warrants part of the placement?

Yes. The financing included pre-funded warrants in lieu of common shares for certain purchasers. The exact later unexercised balance is not verified. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/d48818d8k.htm)

### Does the resale prospectus provide new issuer cash from shareholder sales?

No. The prospectus states that the issuer will not receive proceeds from selling-stockholder sales. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526399452/d546679d424b3.htm)

### Did MapLight complete a reverse split?

The filings describe a one-for-16.8 common-stock consolidation in 2025-10. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/mplt-20251231.htm)

### Who is the auditor?

The annual audit is signed by RSM US LLP, which says it has served since 2020. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/mplt-20251231.htm)

### Did a large holder report falling below five percent?

Novo Holdings A/S reported that it ceased to own more than five percent on 2026-07-30. That is a dated filing position, not a current holding certification. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000138832526000034/xslSCHEDULE_13D_X02/primary_doc.xml)

### Are the resale table after-offering holdings actual completed sales?

No. The selling-stockholder table is hypothetical and assumes covered shares are sold; registration does not prove a sale occurred. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526399452/d546679d424b3.htm)

### Is a current delisting threat verified?

That is a research limit rather than a guarantee of future listing compliance. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/mplt-20260630.htm)

### Was unresolved substantial doubt verified in the latest report?

The report includes a going-concern discussion and says resources cover at least twelve months. No substantial doubt phrase was found; this is not a financial-safety assurance. [Source](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/mplt-20260630.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MPLT on TradingView](https://www.tradingview.com/symbols/NASDAQ-MPLT/).

## SEC filings and registration

- **SEC name**: MapLight Therapeutics, Inc.

- **CIK**: 1770069

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: MPLT (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 800 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063

- **Phone**: 650-839-4360

- **Shares outstanding**: 42,436,326 as of 2026-03-19 (10-K filed 2026-03-26)

- **Former names**: Alvarado Therapeutics, Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [S-1](https://www.sec.gov/Archives/edgar/data/1770069/000119312526386648/d546679ds1.htm) filed 2026-09-09
- [10-Q](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/mplt-20260630.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/d48818d8k.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/d139086d8k.htm) filed 2026-07-27
- [8-K](https://www.sec.gov/Archives/edgar/data/1770069/000119312526280243/d119921d8k.htm) filed 2026-06-24
- [8-K](https://www.sec.gov/Archives/edgar/data/1770069/000119312526276691/d31456d8k.htm) filed 2026-06-22
- [8-K](https://www.sec.gov/Archives/edgar/data/1770069/000119312526276065/d227825d8k.htm) filed 2026-06-18
- [10-Q](https://www.sec.gov/Archives/edgar/data/1770069/000119312526224129/mplt-20260331.htm) filed 2026-05-14

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001770069), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

MapLight Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MPLT, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: MapLight Therapeutics, Inc.

- **Ticker**: MPLT

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US56565P1030

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MPLT/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/maplight-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "MapLight Therapeutics (MPLT) news: IPO and offering", 2026-10-31, https://aibio.space/companies/maplight-therapeutics/